SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...
(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company, made waves in the stock market this week, with its stock price surging a staggering 133.90% to $5.52 during Tuesday’s ...
With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...
The proportion of patients who have been diagnosed with cancer at an early stage in England is at its highest ever level ...
Immuneering Corporation (IMRX) stock gains as company announces positive data for pancreatic cancer treatment and plans to ...
Shares of Immuneering Corporation (NASDAQ:IMRX) surged 55% following the release of encouraging data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The Cambridge-based ...
Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will ...
A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...
Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...
Researchers have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects. By applying brief, localized pulses of magnetic fields, the team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback